摘要:
Immunoconjugués destinés à acheminer sélectivement une cytokine à une cellule cible. Les immunoconjugués comprennent une chaîne lourde d'immunoglobulines ayant une spécificité vis-à-vis de la cellule cible, telle qu'une cellule cancéreuse ou infectée par un virus, ainsi qu'une cytokine, telle qu'une lymphotoxine, un facteur de nécrose tumorale alpha, de l'interleukine-2, ou un facteur stimulant les colonies de granulocytes macrophages, jointe par l'intermédiaire d'un acide aminé à terminaison amino Aits à la terminaison carboxy-A de l'immunoglobuline. L'invention concerne également des séquences d'acides nucléiques codant ces immunoconjugués ainsi que leurs procédés de préparation selon des techniques de génie génétique.
摘要:
A physiologically active polypeptide which has a lymphotoxin activity and is stable and resistant to decomposition-causing factors during purification and storage and which is substantially free of impurities. It is useful as an antitumour agent, and has the following sequence:
摘要翻译:一种生理活性多肽,其具有淋巴毒素活性并且在纯化和储存期间是稳定的并且对分解引起的因子具有抗性并且基本上不含杂质。 作为抗肿瘤剂有用,具有以下顺序: p
摘要:
Methods and compositions are provided for the purification of a protein identified as tumor necrosis factor from nonrecombinant and recombinant sources, the preparation of nucleic acid encoding this tumor necrosis factor and for its expression in recombinant hosts. This tumor necrosis factor is used in the therapeutic treatment of malignant tumors, either alone or in synergistic combination with an interferon.
摘要:
Lymphotoxin-producing human T-cell hybridomas are incubated in a medium containing phorbol myristate acetate, concanavalin A or a mixture thereof, the resulting cells are fractionated by sucrose density gradient centrifugation method to isolate a messenger RNA in l2.6S to l4.6S fractions, and a gene containing a part encoding a polypeptide having a lymphotoxin-activity is prepared from the messenger RNA. The gene is represented by the base sequence of the Table l as herein given. Using the present gene, a new lymphotoxin having the amino acid sequence (I) or (II) as given herein can be obtained by genetic engineering technology.